Citations 72

Cardiopulmonary Failure in Chronic Obstructive Pulmonary Disease (COPD): The Subpopulations and Intermediate Outcome Measures in COPD and Heart Failure Study (SPIROMICS HF)

C105. RESPIRATORY REVELATIONS: EPIDEMIOLOGIC STUDIES IN ASTHMA, COPD, AND LUNG FUNCTION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6771-A6771

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6771

ALbuterol-budesonide Treatment in Acute Airway Obstruction: Design of the ALTA Study

C31. WHAT'S NEW IN CLINICAL ASTHMA | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5282-A5282

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5282

Associations of COPD and Related Outcomes With COVID-19 Hospitalization or Death: The C4R, Copdgene, and Spiromics Studies

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6817-A6817

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6817

Association of Pre-pandemic High Attenuation Areas on Lung CT and COVID-19 Hospitalization and Death: The C4R Study

C107. MICROBIAL RESPIRATORY INFECTIONS DISCOVERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6814-A6814

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6814

Cell-Free DNA to Predict Severe Exacerbations in Chronic Obstructive Pulmonary Disease

A101. FULL METAL JACKET TARGETING COPD AND CHRONIC AIRWAYS DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2798-A2798

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2798

Developing a Machine Learning Algorithm That Analyzes Voice Patterns to Identify Risk of Aspiration

A13. TOWARDS IMPLEMENTATION: NEW BIOMARKERS IN ILD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1004-A1004

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1004

Association of CT-Assessed Dysanapsis With Interstitial Lung Abnormalities in Older Adults

A46. DIAGNOSIS AND MONITORING OF ILD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1746-A1746

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1746

Proteomics of CT Emphysema Subtypes. The Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)

A29. WHAT IS YOUR DAMAGE? IMAGING-BASED PHENOTYPES OF COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1254-A1254

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1254

Air Pollution Exposure and Interstitial Lung Features in SPIROMICS Participants with Chronic Obstructive Pulmonary Disease

Annals of the American Thoracic Society | April 3, 2024 | Volume: 21 | Issue: 9 | Pages: 1251-1260

10.1513/annalsats.202308-741oc | PMID 38568439

Abstract Rationale It is unknown whether air pollution is associated with radiographic features of interstitial lung disease in individuals with chronic obstructive pulmonary disease (COPD). Objectives To determine whether air pollution increases the prevalence of interstitial lung abnormalities (ILA) or percent high-attenuation areas (HAA) on computed tomography (CT) in individuals with a heavy smoking history and COPD. Methods We performed a cross-sectional study of SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study), focused on current or former smokers with COPD. Ten-year exposure to particulate matter ⩽2.5 μm in aerodynamic diameter (PM2.5), nitrogen oxides (NOx), nitrogen dioxide (NO2), and ozone before enrollment CT (completed between 2010 and 2015) were estimated with validated spatiotemporal models at residential addresses. We applied adjusted multivariable modified Poisson regression and linear regression to investigate associations between pollution exposure and relative risk (RR) of ILA or increased percent HAA (between −600 and −250 Hounsfield units), respectively. We assessed for effect modification by MUC5B-promoter polymorphism (variant allele carriers GT or TT vs. GG at rs3705950), smoking status, sex, and percent emphysema. Results Among 1,272 participants with COPD assessed for HAA, 424 were current smokers, and 249 were carriers of the variant MUC5B allele. A total of 519 participants were assessed for ILA. We found no association between pollution exposure and ILA or HAA. Associations between pollutant exposures and risk of ILA were modified by the presence of MUC5B polymorphism (P value interaction term for NOx = 0.04 and PM2.5 = 0.05) and smoking status (P value interaction term for NOx = 0.05; NO2 = 0.01; and ozone = 0.05). With higher exposure to NOx and PM2.5, MUC5B variant carriers had an increased risk of ILA (RR per 26 ppb NOx, 2.41; 95% confidence interval [CI], 0.97–6.0; and RR per 4 μg ⋅ m−3 PM2.5, 1.43; 95% CI, 0.93–2.2, respectively). With higher exposure to NO2, former smokers had an increased risk of ILA (RR per 10 ppb, 1.64; 95% CI, 1.0–2.7). Conclusions Exposure to ambient air pollution was not associated with interstitial features on CT in this population of heavy smokers with COPD. MUC5B modified the association between pollution and ILA, suggesting that gene–environment interactions may influence prevalence of interstitial lung features in COPD.
The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study

American Journal of Respiratory and Critical Care Medicine | March 20, 2024 | Volume: 210 | Issue: 10 | Pages: 1210-1218

10.1164/rccm.202310-1965oc | PMID 38507607

Abstract Rationale Individuals with chronic obstructive pulmonary disease (COPD) have airflow obstruction and maldistribution of ventilation. For those living at high altitude, any gas exchange abnormality is compounded by reduced partial pressures of inspired oxygen. Objectives Does residence at higher altitude exposure affect COPD outcomes, including lung function, imaging characteristics, symptoms, health status, functional exercise capacity, exacerbations, and mortality? Methods From the SPIROMICS (Subpopulation and Intermediate Outcome Measures in COPD Study) cohort, we identified individuals with COPD living below 1,000 ft (305 m) elevation (n = 1,367) versus above 4,000 ft (1,219 m) elevation (n = 288). Multivariable regression models were used to evaluate associations of exposure to high altitude with COPD-related outcomes. Measurements and Main Results Living at higher altitude was associated with reduced functional exercise capacity as defined by 6-minute-walk distance (−32.3 m [95% confidence interval, −49.8 to −14.8 m]). There were no differences in patient-reported outcomes as defined by symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scale), or health status (St. George’s Respiratory Questionnaire). Higher altitude was not associated with a different rate of FEV1 decline. Higher altitude was associated with lower odds of severe exacerbations (incidence rate ratio, 0.65 [95% confidence interval, 0.46 to 0.90]). There were no differences in small airway disease, air trapping, or emphysema. In longitudinal analyses, higher altitude was associated with increased mortality (hazard ratio, 1.25 [95% confidence interval, 1.0 to 1.55]); however, this association was no longer significant when accounting for air pollution. Conclusions Long-term altitude exposure is associated with reduced functional exercise capacity in individuals with COPD, but this did not translate into differences in symptoms or health status. In addition, long-term high-altitude exposure did not affect progression of disease as defined by longitudinal changes in spirometry. Clinical trial registered with www.clinicaltrials.gov (NCT 01969344).